Showing results (5621-5630 of 9,342) with videos related to
Sort By:
Pageof 935
Cancer Medicine|June 12, 2021
Preoperative histogram parameters of dynamic contrast-enhanced MRI as a potential imaging biomarker for assessing the expression of Ki-67 in prostate cancerYongsheng Zhang, Zhiping Li, Chen Gao, et al.Cancer Medicine|May 23, 2022
Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitorsLu-Shan Xiao, Cheng-Yi Hu, Hao Cui, et al.Cancer Medicine|May 24, 2022
First-line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non-small cell lung cancer with EGFR exon 20 insertions: Real-world evidence from ChinaGuangjian Yang, Yaning Yang, Runze Liu, et al.Cancer Medicine|May 24, 2022
A novel prognostic model for papillary thyroid cancer based on epithelial-mesenchymal transition-related genesRui Liu, Zhen Cao, Meng Pan, et al.Cancer Medicine|May 25, 2022
Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancerYuichiro Doki, Makoto Ueno, Chih-Hung Hsu, et al.Cancer Medicine|May 11, 2022
Dynamic monitoring serum tumor markers to predict molecular features of EGFR-mutated lung cancer during targeted therapyZhuxing Chen, Liping Liu, Feng Zhu, et al.Cancer Medicine|May 11, 2022
The impact of antibiotic selection and interval time among advanced non-small cell lung cancer patients receiving prior antibacterial treatment and first-line chemotherapyXiaoman Tian, Ting Mei, Min Yu, et al.Cancer Medicine|May 13, 2022
Prognostic value of IGFBP2 in various cancers: a systematic review and meta-analysisBiao Zhang, Chao-Qun Hong, Yu-Hao Luo, et al.Cancer Medicine|May 26, 2022
Alectinib versus crizotinib in ALK-positive advanced non-small cell lung cancer and comparison of next-generation TKIs after crizotinib failure: Real-world evidenceYurong Wang, Shujing Shen, Peizhu Hu, et al.Cancer Medicine|May 26, 2022
"It's something I'll do until I die": A qualitative examination into why older women in the U.S. continue screening mammographyLaura E Brotzman, Rachel C Shelton, Jessica D Austin, et al.Pageof 935